Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity. Parameters associated with outcomes in pretreated MSI/dMMR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback